Protagonist Therapeutics, Inc. (PTGX)
154.70
+0.38
(+0.25%)
USD |
NASDAQ |
Aug 24, 16:00
154.70
0.00 (0.00%)
After-Hours: 20:00
Protagonist Therapeutics Net Income (Quarterly) : 162.85M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 162.85M |
| March 31, 2026 | 3.783M |
| December 31, 2025 | -44.38M |
| September 30, 2025 | -39.34M |
| June 30, 2025 | -34.77M |
| March 31, 2025 | -11.66M |
| December 31, 2024 | 131.67M |
| September 30, 2024 | -33.21M |
| June 30, 2024 | -30.62M |
| March 31, 2024 | 207.34M |
| December 31, 2023 | 27.34M |
| September 30, 2023 | -34.10M |
| June 30, 2023 | -38.46M |
| March 31, 2023 | -33.72M |
| December 31, 2022 | -34.19M |
| September 30, 2022 | -31.23M |
| June 30, 2022 | -41.04M |
| March 31, 2022 | -20.93M |
| December 31, 2021 | -36.91M |
| September 30, 2021 | -33.80M |
| June 30, 2021 | -30.84M |
| March 31, 2021 | -24.00M |
| Date | Value |
|---|---|
| December 31, 2020 | -18.89M |
| September 30, 2020 | -7.763M |
| June 30, 2020 | -19.42M |
| March 31, 2020 | -20.08M |
| December 31, 2019 | -17.50M |
| September 30, 2019 | -16.41M |
| June 30, 2019 | -29.17M |
| March 31, 2019 | -14.10M |
| December 31, 2018 | -13.86M |
| September 30, 2018 | -8.735M |
| June 30, 2018 | -8.663M |
| March 31, 2018 | -7.661M |
| December 31, 2017 | -3.052M |
| September 30, 2017 | -4.825M |
| June 30, 2017 | -14.98M |
| March 31, 2017 | -14.10M |
| December 31, 2016 | -11.25M |
| September 30, 2016 | -7.084M |
| June 30, 2016 | -7.098M |
| March 31, 2016 | -11.75M |
| March 31, 2015 | -2.697M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -10.50B |
| Insmed, Inc. | -13.24M |
| Madrigal Pharmaceuticals, Inc. | -57.94M |
| AbbVie, Inc. | 3.604B |
| PTC Therapeutics, Inc. | 83.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 213.48M |
| Total Expenses (Quarterly) | 50.63M |
| EPS Diluted (Quarterly) | 2.293 |
| Enterprise Value | 9.207B |
| Gross Profit Margin (Quarterly) | 99.81% |
| Profit Margin (Quarterly) | 76.28% |
| Earnings Yield | 0.67% |
| Operating Earnings Yield | 0.56% |
| Normalized Earnings Yield | 0.6703 |